Abstract
IntroductionPolypoidal choroidal vasculopathy (PCV) is a special subtype of AMD, which is one of the leading threats to vision health worldwide. At this time, many aspects of PCV, from how it works to potential treatments, remain a mystery. In this study, we explored the frontier researches and revealed the study trends within the study of PCV.MethodsWe collected all the publications in this field from 2001 to 2020, analyzed trends within them, and defined the contributions of various countries/regions, institutions, authors, and journals. Additionally, VOSviewer software was used to define the hot keywords in this field.ResultsA total of 1,190 publications were ultimately examined; We found that PCV is becoming an increasingly relevant topic of research, and that Japan has contributed the most publications (428), the most citations (14,504 in total), and the highest H-index value (62) to the field. Our keywords analysis was classified into four clusters to show the hotspots within the study of PCV, namely mechanism-related, imaging-related, prognosis-related, and therapy-related topics. The average years in which the keywords appeared the most were also calculated, and we identified anti-VEGF therapy, anti-complement therapy and angiography as having been the main focus in recent years.ConclusionsThese results helped clarify the comprehensive research progress that has been made as well as the future trends in the study of PCV, which can assist and guide future research.
Highlights
Polypoidal choroidal vasculopathy (PCV) is a special subtype of AMD, which is one of the leading threats to vision health worldwide
Bibliometric of Polypoidal Choroidal Vasculopathy patients diagnosed with AMD were classified as PCV, according to indocyanine green angiography (ICGA), while only about 10% of European AMD patients were classified as PCV [4,5,6]
ICGA, an invasive examination, is currently the gold standard for PCV diagnosis [8], though its incommodious diagnostic criteria may lead to the underestimation of the overall prevalence of PCV [9]
Summary
Polypoidal choroidal vasculopathy (PCV) is a special subtype of AMD, which is one of the leading threats to vision health worldwide. At this time, many aspects of PCV, from how it works to potential treatments, remain a mystery. Bibliometric of Polypoidal Choroidal Vasculopathy patients diagnosed with AMD were classified as PCV, according to indocyanine green angiography (ICGA), while only about 10% of European AMD patients were classified as PCV [4,5,6] These different clinical manifestations suggest the distinct pathological differences between PCV and AMD. Both the LAPTOP study and the EVEREST study confirmed the better visual outcome of antiVEGF monotherapy as compared to photodynamic therapy (PDT) [10, 11]; anti-VEGF requires repeated injections and its effect on the polyp regression rate in patients (17–40%) is limited [1, 12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
